Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 66Head & Neck 23CNS 20Endocrine 15Tumor-Agnostic 13Gastrointestinal 9Thoracic 8Plasma cell 7Other hematologic neoplasm 7Lymphoid 5Myeloid 4Sarcoma 2Other solid neoplasm 2Gynecologic 2Genitourinary 2Breast 2Other neoplasm 1Classical hematology 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumor 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × dabrafenib × Other solid neoplasm × Clear all
NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Tianjin Medical University Second Hospital

Phase 2 Recruiting
300 enrolled
Other solid neoplasm

Solid Tumor

NCT01713972 2019-03-01

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡